NOVEMBER 03, 2022
Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19 Biophytis released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure. A reduction in the risk of early death or respiratory failure at…